A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Latest Information Update: 10 Oct 2024
At a glance
- Drugs Trospium chloride/xanomeline (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms ARISE
- Sponsors Karuna Therapeutics
- 18 Jun 2024 Planned End Date changed from 1 Feb 2025 to 28 Feb 2025.
- 18 Jun 2024 Planned primary completion date changed from 1 Feb 2025 to 28 Feb 2025.
- 20 Mar 2024 Planned End Date changed from 1 Oct 2024 to 1 Feb 2025.